Skip to main content
. 2017 Dec;12(6):517–525. doi: 10.4103/1735-5362.217432

Table 2.

Dose reduction index in double and triple combinations of 17-AAG, capecitabine, and oxaliplatin in HCT-116 and HT-29 cell lines.

graphic file with name RPS-12-517-g004.jpg